How would you manage a patient with high risk triple negative breast cancer with metastatic disease after recent adjuvant AC-T?
Would you consider still immunotherapy even if aggressive disease vs single agent chemotherapy?
Answer from: Medical Oncologist at Academic Institution
If she relapsed within 12 months of her adjuvant paclitaxel, then I would consider her TNBC taxane resistant. These patients weren't enrolled in Impassion130 and many first line trials exclude patients with short DFI. If a trial is available, consider it whenever possible. I would do BRCA germline t...
Sign in or Register to read more